PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10296128

AIDS awareness study.

B Eckstein
View original source ↗Export metadata ↓

Abstract

The Center for Disease Control was given the responsibility for developing and disseminating information about AIDS. To that end, the Center retained Ogilvy & Mather Advertising to prepare an extensive public service campaign on the subject. In order to develop the most effective communication, research was needed to establish the level of public awareness and to explore attitudes toward this disease. The study presented here deals with the attitudes of women. It was conducted by Blanka Eckstein of B. Eckstein Qualitative Research and by Paul Murdoch, Research Director of Ogilvy & Mather Atlanta. Findings from other population groups (i.e., teenage boys, gay men, parents of teens) were reported by other researchers. Address correspondence to Blanka Eckstein Social Science Applications, 251 Lexington Avenue, New York, NY 10016.

Explore related subjects

Acquired Immunodeficiency SyndromeAsianAttitude to HealthContraceptive Devices, MaleFemaleFloridaHealth EducationHispanic or LatinoHumansMass MediaNew York CityTelevisionWomenJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Eckstein. 1989. AIDS awareness study.. https://doi.org/10.1300/j026v06n04_06

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

The spectrum of HIV-1 related cancers in South Africa.

Despite the high prevalence of infection by the Human Immunodeficiency Virus (HIV) in South Africa, information on its association with cancer is sparse. Our study was carried out to examine the relationship between HIV and a number of cancer types or sites that are common in South Africa. A total of 4,883 subjects, presenting with a cancer or cardiovascular disease at the 3 tertiary referral hospitals in Johannesburg, were interviewed and had blood tested for HIV. Odds ratios associated with HIV infection were calculated by using unconditional logistic regression models for 16 major cancer types where data was available for 50 or more patients. In the comparison group, the prevalence of HIV infection was 8.3% in males and 9.1% in females. Significant excess risks associated with HIV infection were found for Kaposi's sarcoma (OR=21.9, 95% CI=12.5-38.6), non-Hodgkin lymphoma (OR=5.0, 95%CI=2.7-9.5), vulval cancer (OR=4.8, 95%CI= 1.9-12.2) and cervical cancer (OR= 1.6, 95%CI= 1.1-2.3) but not for any of the other major cancer types examined, including Hodgkin disease, multiple myeloma and lung cancer. In Johannesburg, South Africa, HIV infection was associated with significantly increased risks of Kaposi's sarcoma, non-Hodgkin lymphoma and cancers of the cervix and the vulva. The relative risks for Kaposi's sarcoma and non-Hodgkin lymphoma associated with HIV infection were substantially lower than those found in the West.

Acquired Immunodeficiency Syndrome↗
PubMed2000

Ribozyme therapy for HIV infection.

Within the past few years encouraging progress has been made in the treatment of HIV-1 infection, largely due to the combined use of HIV-1 protease inhibitors with nucleoside and non-nucleoside reverse transcriptase inhibitors. Despite this, HIV-1 infection is still a major global problem and the emergence of a drug resistant virus is ever present. There is a continuing need to develop new therapeutic strategies as well as improve upon all forms of existing therapies for the treatment of this viral infection. It has now been almost a decade since the first demonstration that ribozymes can effectively inhibit HIV-1 infectious spread in cell culture. Since then, ribozymes have progressed into human clinical trials primarily through gene therapy approaches. This progression brings ribozymes into the forefront as an important addition to the growing arsenal of anti-HIV-1 weapons. The following review covers the developments in anti-HIV-1 ribozyme usage over the past decade and summarizes the current state of ribozyme development for the purpose of inhibiting HIV-1 infection.

Acquired Immunodeficiency Syndrome↗